基于NLRP3炎症小体探讨中医药防治结直肠癌的相关进展

刘吉祥; 王一冲; 孔佑甲; 彭红叶; 姚树坤

doi:10.3969/j.issn.1671-038X.2022.10.13

基于NLRP3炎症小体探讨中医药防治结直肠癌的相关进展

- 1.
  北京中医药大学研究生院(北京，100029)
- 2.
  中日友好医院消化内科
基金项目:
十病十药研发(No：Z171100001717008)

详细信息

通讯作者: 姚树坤，E-mail：yao_sk@163.com

^Δ审校者

中图分类号: R73

收稿日期: 2022-06-08

刊出日期: 2022-10-15

Exploring the progress of Traditional Chinese Medicine against colorectal cancer based on NLRP3 inflammasome

- 1.
  Graduate School of Beijing University of Chinese Medicine, Beijing, 100029, Chian
- 2.
  Department of Gastroenterology, China-Japan Friendship Hospital

More Information

Corresponding author: YAO Shukun, E-mail: yao_sk@163.com

Received Date: 08 June 2022

Publish Date: 15 October 2022

摘要

摘要: 近年来结直肠癌的发病率和病死率逐步上升，其发病机制为肠道慢性炎症、免疫失调、菌群失衡等。NLRP3炎症小体是人体固有免疫系统的重要组成部分，能够被多种物质激活，诱发肠道慢性炎症及免疫失调、细胞焦亡等，目前已被证实与结直肠癌的发生、发展密切相关。该文根据国内外最新研究，聚焦NLRP3炎症小体与结直肠癌的关系，综述中医药通过NLRP3炎症小体通路治疗结直肠癌的研究进展。
- NLRP3炎症小体 /
- 结直肠癌 /
- 中医
Abstract: The incidence and mortality of colorectal cancer(CRC) in China have gradually increased in recent years, and its pathogenesis is based on chronic intestinal inflammation, immune dysregulation and flora imbalance, etc. NOD-like receptor protein 3 (NLRP3) inflammasome an important component of the body's intrinsic immune system, capable of being activated by a variety of substances to induce chronic inflammation and immune dysregulation and cellular scorching in the intestine, and have now been shown to be closely associated with CRC development. Therefore, this paper focuses on the relationship between NLRP3 inflammasome and CRC based on the latest research at home and abroad, and reviews the research progress of Traditional Chinese Medicine in treating CRC through the NLRP3 inflammasome pathway.
- NOD-like receptor protein 3 inflammasome /
- colorectal cancer /
- Traditional Chinese Medicine

HTML全文

参考文献(55)

[1]	Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016[J]. J National Cancer Center, 2022, 2(1): 1-9. doi: 10.1016/j.jncc.2022.02.002
[2]	徐玉彬, 张培建, 王超臣. 结直肠癌的病因及发病机制的研究进展[J]. 中华临床医师杂志(电子版), 2015, 9(15): 2912-2915. doi: 10.3877/cma.j.issn.1674-0785.2015.15.029
[3]	Keshavarz S, Koushki K, Ayati SH, et al. Inflammasomes and Colorectal Cancer[J]. Cells, 2021, 10(9): 2172. doi: 10.3390/cells10092172
[4]	Ngui I, Perera AP, Eri R. Does NLRP3 Inflammasome and Aryl Hydrocarbon Receptor Play an Interlinked Role in Bowel Inflammation and Colitis-Associated Colorectal Cancer?[J]. Molecules, 2020, 25(10): 2427. doi: 10.3390/molecules25102427
[5]	Cambui R, do Espírito Santo GF, Fernandes FP, et al. Double-edged sword of inflammasome genetics in colorectal cancer prognosis[J]. Clin Immunol, 2020, 213: 108373. doi: 10.1016/j.clim.2020.108373
[6]	Karki R, Kanneganti TD. Diverging inflammasome signals in tumorigenesis and potential targeting[J]. Nat Rev Cancer, 2019, 19(4): 197-214. doi: 10.1038/s41568-019-0123-y
[7]	Hou J, Zhao R, Xia W, et al. PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis[J]. Nat Cell Biol, 2020, 22(10): 1264-1275. doi: 10.1038/s41556-020-0575-z
[8]	Bauer C, Duewell P, Lehr HA, et al. Protective and aggravating effects of Nlrp3 inflammasome activation in IBD models: influence of genetic and environmental factors[J]. Dig Dis, 2012, 30(Suppl 1): 82-90.
[9]	Huber S, Gagliani N, Zenewicz LA, et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine[J]. Nature, 2012, 491(7423): 259-263. doi: 10.1038/nature11535
[10]	Fruhbeck G, Mentxaka A, Ahechu P, et al. The Differential Expression of the Inflammasomes in Adipose Tissue and Colon Influences the Development of Colon Cancer in a Context of Obesity by Regulating Intestinal Inflammation[J]. J Inflamm Res, 2021, 14: 6431-6446. doi: 10.2147/JIR.S335882
[11]	Son HJ, Sohn SH, Kim N, et al. Effect of Estradiol in an Azoxymethane/Dextran Sulfate Sodium-Treated Mouse Model of Colorectal Cancer: Implication for Sex Difference in Colorectal Cancer Development[J]. Cancer Res Treat, 2019, 51(2): 632-648. doi: 10.4143/crt.2018.060
[12]	Liu L, Dong W, Wang S, et al. Deoxycholic acid disrupts the intestinal mucosal barrier and promotes intestinal tumorigenesis[J]. Food Funct, 2018, 9(11): 5588-5597. doi: 10.1039/C8FO01143E
[13]	Shao X, Lei Z, Zhou C. NLRP3 Promotes Colorectal Cancer Cell Proliferation and Metastasis via Regulating Epithelial Mesenchymal Transformation[J]. Anticancer Agents Med Chem, 2020, 20(7): 820-827. doi: 10.2174/1871520620666200220112741
[14]	Deng Q, Geng Y, Zhao L, et al. NLRP3 inflammasomes in macrophages drive colorectal cancer metastasis to the liver[J]. Cancer Lett, 2019, 442: 21-30. doi: 10.1016/j.canlet.2018.10.030
[15]	Wang B, Li H, Wang X, et al. The association of aberrant expression of NLRP3 and p-S6K1 in colorectal cancer[J]. Pathol Res Pract, 2020, 216(1): 152737. doi: 10.1016/j.prp.2019.152737
[16]	Shi F, Wei B, Lan T, et al. Low NLRP3 expression predicts a better prognosis of colorectal cancer[J]. Biosci Rep, 2021, 41(4): BSR20210280. doi: 10.1042/BSR20210280
[17]	Marandi Y, Hashemzade S, Tayebinia H, et al. NLRP3-inflammasome activation is associated with epithelial-mesenchymal transition and progression of colorectal cancer[J]. Iran J Basic Med Sci, 2021, 24(4): 483-492.
[18]	Ding Y, Yan Y, Dong Y, et al. NLRP3 promotes immune escape by regulating immune checkpoints: A pan-cancer analysis[J]. Int Immunopharmacol, 2022, 104: 108512. doi: 10.1016/j.intimp.2021.108512
[19]	Lu F, Zhao Y, Pang Y, et al. NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma[J]. Cancer Lett, 2021, 497: 178-189. doi: 10.1016/j.canlet.2020.10.024
[20]	MakAnyengo R, Duewell P, Reichl C, et al. Nlrp3-dependent IL-1β inhibits CD103⁺ dendritic cell differentiation in the gut[J]. JCI Insight, 2018, 3(5): e96322. doi: 10.1172/jci.insight.96322
[21]	Daley D, Mani VR, Mohan N, et al. NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma[J]. J Exp Med, 2017, 214(6): 1711-1724. doi: 10.1084/jem.20161707
[22]	吴长有. Th17细胞: 一种新的效应CD4⁺T细胞亚群[J]. 细胞与分子免疫学杂志, 2006(6): 695-697. doi: 10.3321/j.issn:1007-8738.2006.06.001
[23]	姚金晶, 陈宜涛. Th1/Th2平衡调节与疾病发生的研究进展[J]. 现代生物医学进展, 2009, 9(13): 2597-2600. https://www.cnki.com.cn/Article/CJFDTOTAL-SWCX200913062.htm
[24]	Mutala LB, Deleine C, Karakachoff M, et al. The Caspase-1/IL-18 Axis of the Inflammasome in Tumor Cells: A Modulator of the Th1/Tc1 Response of Tumor-Infiltrating T Lymphocytes in Colorectal Cancer[J]. Cancers(Basel), 2021, 13(2): 189.
[25]	Gong W, Liu P, Zhao F, et al. STING-mediated Syk Signaling Attenuates Tumorigenesis of Colitis-associated Colorectal Cancer Through Enhancing Intestinal Epithelium Pyroptosis[J]. Inflamm Bowel Dis, 2022, 28(4): 572-585. doi: 10.1093/ibd/izab217
[26]	Tang Z, Ji L, Han M, et al. Pyroptosis is involved in the inhibitory effect of FL118 on growth and metastasis in colorectal cancer[J]. Life Sci, 2020, 257: 118065. doi: 10.1016/j.lfs.2020.118065
[27]	Derangere V, Chevriaux A, Courtaut F, et al. Liver X receptor β activation induces pyroptosis of human and murine colon cancer cells[J]. Cell Death Differ, 2014, 21(12): 1914-1924. doi: 10.1038/cdd.2014.117
[28]	Ma Y, Chen Y, Lin C, et al. Biological functions and clinical significance of the newly identified long non-coding RNA RP1-85F18.6 in colorectal cancer[J]. Oncol Rep, 2018, 40(5): 2648-2658.
[29]	Wu LS, Liu Y, Wang XW, et al. LPS Enhances the Chemosensitivity of Oxaliplatin in HT29 Cells via GSDMD-Mediated Pyroptosis[J]. Cancer Manag Res, 2020, 12: 10397-10409. doi: 10.2147/CMAR.S244374
[30]	Dupaul-Chicoine J, Arabzadeh A, Dagenais M, et al. The Nlrp3 Inflammasome Suppresses Colorectal Cancer Metastatic Growth in the Liver by Promoting Natural Killer Cell Tumoricidal Activity[J]. Immunity, 2015, 43(4): 751-763. doi: 10.1016/j.immuni.2015.08.013
[31]	Hirota SA, Ng J, Lueng A, et al. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis[J]. Inflamm Bowel Dis, 2011, 17(6): 1359-1372. doi: 10.1002/ibd.21478
[32]	Henao-Mejia J, Elinav E, Jin C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity[J]. Nature, 2012, 482(7384): 179-185. doi: 10.1038/nature10809
[33]	陈叶, 刘金涛, 朱源, 等. 大肠癌中医辨证及治疗概况[J]. 中国肿瘤, 2015, 24(4): 319-324. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU201504017.htm
[34]	杨宇飞. 中医药在结直肠癌治疗中的优势与展望[J]. 中国中西医结合杂志, 2020, 40(11): 1294-1297. doi: 10.7661/j.cjim.20201011.191
[35]	Qin Y, Yu Y, Yang C, et al. Atractylenolide I Inhibits NLRP3 Inflammasome Activation in Colitis-Associated Colorectal Cancer via Suppressing Drp1-Mediated Mitochondrial Fission[J]. Front Pharmacol, 2021, 12: 674340. doi: 10.3389/fphar.2021.674340
[36]	He Q, Li Z, Wang Y, et al. Resveratrol alleviates cerebral ischemia/reperfusion injury in rats by inhibiting NLRP3 inflammasome activation through Sirt1-dependent autophagy induction[J]. Int Immunopharmacol, 2017, 50: 208-215. doi: 10.1016/j.intimp.2017.06.029
[37]	Elshaer M, Chen Y, Wang XJ, et al. Resveratrol: An overview of its anti-cancer mechanisms[J]. Life Sci, 2018, 207: 340-349. doi: 10.1016/j.lfs.2018.06.028
[38]	Dai G, Jiang Z, Sun B, et al. Caffeic Acid Phenethyl Ester Prevents Colitis-Associated Cancer by Inhibiting NLRP3 Inflammasome[J]. Front Oncol, 2020, 10: 721. doi: 10.3389/fonc.2020.00721
[39]	Qiao S, Lv C, Tao Y, et al. Arctigenin disrupts NLRP3 inflammasome assembly in colonic macrophages via downregulating fatty acid oxidation to prevent colitis-associated cancer[J]. Cancer Lett, 2020, 491: 162-179. doi: 10.1016/j.canlet.2020.08.033
[40]	Xie S, Yang T, Wang Z, et al. Astragaloside attenuates sepsis-induced intestinal barrier dysfunction via suppressing RhoA/NLRP3 inflammasome signaling[J]. Int Immunopharmacol, 2020, 78: 106066. doi: 10.1016/j.intimp.2019.106066
[41]	Guo W, Sun Y, Liu W, et al. Small molecule-driven mitophagy-mediated NLRP3 inflammasome inhibition is responsible for the prevention of colitis-associated cancer[J]. Autophagy, 2014, 10(6): 972-985. doi: 10.4161/auto.28374
[42]	Xu L, Cai P, Li X, et al. Inhibition of NLRP3 inflammasome activation in myeloid-derived suppressor cells by and rographolide sulfonate contributes to 5-FU sensitization in mice[J]. Toxicol Appl Pharmacol, 2021, 428: 115672. doi: 10.1016/j.taap.2021.115672
[43]	毕娉娉. 基于NLRP3炎症小体探讨连翘防治化疗性恶心呕吐作用机制[D]. 广州: 广东药科大学, 2021.
[44]	张文杰. 补中益气丸对IEC-6细胞损伤模型NLRP3炎性体及相关细胞因子的影响[D]. 广州: 广州中医药大学, 2017.
[45]	黎思欣. 溃结灵对UC大鼠肠道内Caspase-1介导细胞焦亡的作用研究[D]. 广州: 广州中医药大学, 2019.
[46]	沈佳雯. 白术黄芪汤通过抑制NLRP3炎症小体治疗DSS诱导的小鼠溃疡性结肠炎[D]. 成都: 西南交通大学, 2018.
[47]	赵卓, 刘林, 宋囡, 等. 半夏泻心汤对溃疡性结肠炎大鼠NLRP3/Caspase-1细胞焦亡通路的影响[J]. 中国实验方剂学杂志, 2022, 28(16): 29-34. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSFX202216004.htm
[48]	吴娜, 万治平, 韩玲, 等. 黄芩汤对溃疡性结肠炎小鼠NLRP3/caspase-1细胞焦亡通路的影响[J]. 中国中药杂志, 2021, 46(5): 1191-1196. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZY202105023.htm
[49]	曲超. 桦褐孔菌多糖对AOM/DSS诱导的结肠炎相关结直肠癌模型小鼠的影响及其机制的初步探讨[D]. 延边: 延边大学, 2019.
[50]	Joshi P, Joshi S, Semwal D, et al. Curcumin: An Insight into Molecular Pathways Involved in Anticancer Activity[J]. Mini Rev Med Chem, 2021, 21(17): 2420-2457. doi: 10.2174/1389557521666210122153823
[51]	但文超, 刘金垒, 何庆勇, 等. 基于网络药理学与数据挖掘探讨中药调节细胞焦亡用药规律[J]. 中国中医药信息杂志, 2021, 28(9): 36-43. https://www.cnki.com.cn/Article/CJFDTOTAL-XXYY202109008.htm
[52]	王容容, 蒋益兰, 田雪飞, 等. 健脾消癌方对结直肠癌移植模型裸鼠NLRP3炎性小体表达及免疫功能的影响[J]. 中华中医药杂志, 2020, 35(8): 3890-3893. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY202008022.htm
[53]	郭垠梅. 西黄丸促进肝癌SMMC-7721细胞发生细胞焦亡作用机制研究[D]. 长沙: 湖南中医药大学, 2021.
[54]	焦建玮, 白玉杰, 白玉莲, 等. 葶苈大枣泻肺汤通过Caspase-1诱导A549细胞焦亡与凋亡的机制[J]. 中国实验方剂学杂志, 2022, 28(6): 54-61. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSFX202206007.htm
[55]	田雯, 刘伟, 李嘉丽, 等. 健脾化瘀解毒方调节NLRP3炎症小体活化的生物信息学研究[J]. 中药新药与临床药理, 2021, 32(9): 1321-1328. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXY202109014.htm